Developer docs
API playgroundTry for free, no card

Search company profiles

Cardiac Dimensions

Full company profile

uuid00009om

Namestring
Cardiac Dimensions
Legal namestring
Cardiac Dimensions Pty. Ltd.
Company typeenum
Private
Founded yearint
2001
Descriptiontext

Cardiac Dimensions is a privately held medical device company founded in 2001 that develops the Carillon Mitral Contour System, a catheter-based transcatheter device intended to treat functional mitral regurgitation (FMR) in heart failure patients via an indirect mitral annuloplasty approach through the coronary sinus. The device uses distal and proximal anchors connected by a shaping ribbon to cinch the mitral valve apparatus without damaging the leaflets, inducing favorable left ventricular remodeling and preserving access to future therapies including cardiac resynchronization. The company is headquartered in Kirkland, Washington, with operational offices in Sydney, Australia and Frankfurt, Germany, and operates with roughly 65 employees. Its core customer is the hospital cardiac catheterization laboratory performing transcatheter mitral valve procedures, with primary end-patients being heart failure patients with reduced or preserved ejection fraction and FMR grades 2+ through 4+.

Cardiac Dimensions generates revenue through direct hardware sales of the Carillon system to hospitals, with full reimbursement in key European markets (notably Germany under DRG) and TGA-approved commercial sales in Australia. The U.S. market is investigational-only, with the device limited to use in the EMPOWER randomized sham-controlled pivotal trial designed to support FDA approval. The company has treated over 1,500 patients cumulatively, holds 30+ US patents, and possesses the most comprehensive longitudinal clinical evidence base in the indirect annuloplasty category, including 5-year multi-center registry data, 10-year survival data, and inclusion in 2021 European Society of Cardiology Guidelines as the first non-TEER device recommended for secondary mitral regurgitation. Over $200 million in total venture funding has been raised across multiple rounds, with the most recent $53 million Series E in March 2025 earmarked to complete the EMPOWER pivotal study and support global commercialization.

Short descriptiontext

Cardiac Dimensions is a privately held medical device company that develops the Carillon Mitral Contour System, a catheter-based transcatheter mitral valve repair device for treating functional mitral regurgitation in heart failure patients, sold to hospital cardiac catheterization labs in Europe and Australia with U.S. approval pending.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersKirkland, United States
HQ citystring
Kirkland
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
transcatheter mitral repair, cardiac medical devices, heart failure treatment, mitral annuloplasty devices, interventional cardiology
Industry3 codes
PRIMARYHLAHAFAL
Cardiac Assist & Heart Failure Therapies (Implantables, Neuromodulation)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
SECONDARYHLAHAFAB
Structural Heart Valves (TAVR/SAVR) & Valve Repair
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
SECONDARYHLAKABAB
Interventional Cardiology (PCI/Structural Heart)
NAICS code2 codes
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
  • Surgical and Medical Instrument Manufacturing339112
SIC code1 code
  • Surgical & Medical Instruments & Apparatus3841
Product category
Transcatheter Mitral Valve Repair Devices
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Carillon Mitral Contour System Sales
TypeHardware Sales
Description

Sale of the Carillon Mitral Contour System, a catheter-based medical device for treating functional mitral regurgitation in heart failure patients. The device is commercially available in Europe and other countries following CE Mark clearance, and is investigational in the U.S. pending FDA approval.

cardiacdimensions.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components2 values
Technology or R&D, Personnel
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1Carillon Mitral Contour System
Description

Catheter-based transcatheter indirect mitral annuloplasty device designed to treat functional mitral regurgitation by reshaping the mitral valve apparatus via the coronary sinus. The only commercially available indirect mitral annuloplasty device.

cardiacdimensions.com
+2 more records
Core offering1 text field

Cardiac Dimensions develops and commercializes the Carillon Mitral Contour System, a catheter-based, minimally invasive device designed to treat functional mitral regurgitation (FMR) in heart failure patients. The device is delivered percutaneously via the coronary sinus and uses distal and proximal anchors connected by a shaping ribbon to reshape the mitral valve apparatus without damaging valve leaflets. It is sold directly to hospitals and cardiac catheterization labs in Europe and Australia, while U.S. use is limited to investigational settings via the EMPOWER pivotal trial.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 7 values shown
  • 97% of patients maintained stable or improved MR grade across all time points through five years
+6 more records
Product overview1 text field

Cardiac Dimensions offers a single flagship product, the Carillon Mitral Contour System, a catheter-based minimally invasive device designed to treat functional mitral regurgitation (FMR) in heart failure patients. The system uses a transcatheter approach via the coronary sinus with distal and proximal anchors connected by a shaping ribbon. The device is CE Marked and commercially available in Europe and other countries that recognize CE Mark, TGA approved in Australia, and is currently under investigation in the U.S. pivotal EMPOWER Trial for FDA approval.

Product and service1 record
1Carillon Mitral Contour System
CategoryTranscatheter Mitral Valve Repair
Description

A catheter-based, minimally invasive transcatheter indirect mitral annuloplasty device that reshapes the mitral valve apparatus via the coronary sinus using distal and proximal anchors connected by a shaping ribbon. Designed for heart failure patients with functional mitral regurgitation (FMR) grades 2+ to 4+. CE Marked, MDR certified, and TGA approved; under U.S. EMPOWER pivotal trial for FDA approval.

Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2026-07-10
Description

Qtis.ai launched its AI-native Clinical Trial Management System (CTMS) with Cardiac Dimensions as the first commercial customer. Cardiac Dimensions will use Qtis.ai's platform for clinical trial management including document management and integrated research operations.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-01-05
Description

Leading center participating in the EMPOWER pivotal trial. Dr. Samir Kapadia serves as national principal investigator for the trial.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-01-05
Description

Leading center participating in the EMPOWER pivotal trial for U.S. regulatory approval.

4Ronald Reagan UCLA Medical Center
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-01-05
Description

Leading center participating in the EMPOWER pivotal trial for U.S. regulatory approval.

cardiacdimensions.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-09-22
Description

ESC Guidelines published recommendations supporting the Carillon Mitral Contour System for treatment of secondary mitral regurgitation. First non-TEER device included in heart failure guidelines.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Corvia Medical develops the Corvia Atrial Shunt (IASD) for heart failure with preserved ejection fraction (HFpEF). It targets an overlapping heart failure patient population through a different interventional mechanism, sharing potential referral channels and clinical thought leaders.

TypeBroad incumbent
Description

Medtronic is developing the Intrepid transcatheter mitral valve replacement (TMVR) system and has broader structural heart portfolio including the Intrepid, Evolut, and Harmony platforms. It is a broad incumbent in cardiovascular devices with overlapping mitral valve treatment ambitions.

TypeEmerging player
Description

Ancora Heart is developing the AccuCinch ventricular restoration system for heart failure patients with functional mitral regurgitation. It is an emerging player addressing an overlapping patient population via a different mechanism (ventricular reshaping rather than annular).

TypeBroad incumbent
Description

Boston Scientific has a structural heart portfolio and has invested in transcatheter mitral and tricuspid valve technologies through acquisitions and partnerships. It competes in the broader cardiovascular space with relevant mitral valve repair and replacement programs.

TypeDirect peer
Description

Edwards Lifesciences markets the PASCAL transcatheter valve repair system for mitral regurgitation, directly competing with both Carillon and MitraClip. The company is a major structural heart player with overlapping catheter-based mitral valve repair technology.

6Polares Medical
TypeEmerging player
Description

Polares Medical is developing a transcatheter mitral valve replacement (TMVR) technology targeting functional mitral regurgitation. It is an emerging structural heart company in the same clinical space with a complementary therapeutic approach.

TypeEmerging player
Description

NeoChord develops transcatheter chordal repair technology for degenerative mitral regurgitation using a transapical approach. It is an emerging player in the minimally invasive mitral valve repair space with a different but adjacent technology approach.

8Abbott
TypeDirect peer
Description

Abbott markets the MitraClip, the leading transcatheter edge-to-edge repair (TEER) device for mitral regurgitation. It is the most commercially successful transcatheter mitral valve repair product and the primary direct competitor to Cardiac Dimensions' Carillon system for treating functional mitral regurgitation.

TypeEmerging player
Description

Valcare Medical is developing transcatheter mitral and tricuspid valve repair and replacement technologies. It is an emerging Israeli medical device company focused on structural heart interventions with overlapping therapeutic goals.

TypeEmerging player
Description

V-Wave is developing interatrial shunts for heart failure with preserved and reduced ejection fraction. While targeting a different mechanism, both companies address the same heart failure population and have overlapping clinical and commercial channels.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance4 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds11 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors24 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Cardiac Dimensions

Transcatheter Mitral Valve Repair Devicescardiacdimensions.com

Cardiac Dimensions is a privately held medical device company that develops the Carillon Mitral Contour System, a catheter-based transcatheter mitral valve repair device for treating functional mitral regurgitation in heart failure patients, sold to hospital cardiac catheterization labs in Europe and Australia with U.S. approval pending.

What Cardiac Dimensions does

Cardiac Dimensions is a privately held medical device company founded in 2001 that develops the Carillon Mitral Contour System, a catheter-based transcatheter device intended to treat functional mitral regurgitation (FMR) in heart failure patients via an indirect mitral annuloplasty approach through the coronary sinus. The device uses distal and proximal anchors connected by a shaping ribbon to cinch the mitral valve apparatus without damaging the leaflets, inducing favorable left ventricular remodeling and preserving access to future therapies including cardiac resynchronization. The company is headquartered in Kirkland, Washington, with operational offices in Sydney, Australia and Frankfurt, Germany, and operates with roughly 65 employees. Its core customer is the hospital cardiac catheterization laboratory performing transcatheter mitral valve procedures, with primary end-patients being heart failure patients with reduced or preserved ejection fraction and FMR grades 2+ through 4+.

Cardiac Dimensions generates revenue through direct hardware sales of the Carillon system to hospitals, with full reimbursement in key European markets (notably Germany under DRG) and TGA-approved commercial sales in Australia. The U.S. market is investigational-only, with the device limited to use in the EMPOWER randomized sham-controlled pivotal trial designed to support FDA approval. The company has treated over 1,500 patients cumulatively, holds 30+ US patents, and possesses the most comprehensive longitudinal clinical evidence base in the indirect annuloplasty category, including 5-year multi-center registry data, 10-year survival data, and inclusion in 2021 European Society of Cardiology Guidelines as the first non-TEER device recommended for secondary mitral regurgitation. Over $200 million in total venture funding has been raised across multiple rounds, with the most recent $53 million Series E in March 2025 earmarked to complete the EMPOWER pivotal study and support global commercialization.

Cardiac Dimensions firmographics

Firmographics
Name
Cardiac Dimensions
Legal name
Cardiac Dimensions Pty. Ltd.
Website
https://cardiacdimensions.com
Company type
Private
Founded year
2001
Operating status
Operating
Headcount range
51–100 employees
Short description
Cardiac Dimensions is a privately held medical device company that develops the Carillon Mitral Contour System, a catheter-based transcatheter mitral valve repair device for treating functional mitral regurgitation in heart failure patients, sold to hospital cardiac catheterization labs in Europe and Australia with U.S. approval pending.
Ownership category
akta.pro rank

Cardiac Dimensions industry classification

Industry
Product category
Transcatheter Mitral Valve Repair Devices
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Surgical and Medical Instrument Manufacturing (339112)
SIC
Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAHAFAL
Cardiac Assist & Heart Failure Therapies (Implantables, Neuromodulation)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
SECONDARYHLAHAFAB
Structural Heart Valves (TAVR/SAVR) & Valve Repair
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
SECONDARYHLAKABAB
Interventional Cardiology (PCI/Structural Heart)

Keywords

  • Transcatheter mitral repair
  • Cardiac medical devices
  • Heart failure treatment
  • Mitral annuloplasty devices
  • Interventional cardiology

Where Cardiac Dimensions is headquartered

Location

Headquarters

HQ city
Kirkland
HQ country
United States
HQ region
North America

Offices3 records

Markets served

Cardiac Dimensions business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel

Revenue model

  1. Carillon Mitral Contour System Sales: Sale of the Carillon Mitral Contour System, a catheter-based medical device for treating functional mitral regurgitation in heart failure patients. The device is commercially available in Europe and other countries following CE Mark clearance, and is investigational in the U.S. pending FDA approval.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

Cardiac Dimensions product offering

Product offering

Core offering

Cardiac Dimensions develops and commercializes the Carillon Mitral Contour System, a catheter-based, minimally invasive device designed to treat functional mitral regurgitation (FMR) in heart failure patients. The device is delivered percutaneously via the coronary sinus and uses distal and proximal anchors connected by a shaping ribbon to reshape the mitral valve apparatus without damaging valve leaflets. It is sold directly to hospitals and cardiac catheterization labs in Europe and Australia, while U.S. use is limited to investigational settings via the EMPOWER pivotal trial.

Product overview

Cardiac Dimensions offers a single flagship product, the Carillon Mitral Contour System, a catheter-based minimally invasive device designed to treat functional mitral regurgitation (FMR) in heart failure patients. The system uses a transcatheter approach via the coronary sinus with distal and proximal anchors connected by a shaping ribbon. The device is CE Marked and commercially available in Europe and other countries that recognize CE Mark, TGA approved in Australia, and is currently under investigation in the U.S. pivotal EMPOWER Trial for FDA approval.

Differentiator

Problem solved

Functional benefit

Brands

  • Carillon Mitral Contour System: Catheter-based transcatheter indirect mitral annuloplasty device designed to treat functional mitral regurgitation by reshaping the mitral valve apparatus via the coronary sinus. The only commercially available indirect mitral annuloplasty device.
  • Carillon
  • EMPOWER Trial

Products and services

  • Carillon Mitral Contour System A catheter-based, minimally invasive transcatheter indirect mitral annuloplasty device that reshapes the mitral valve apparatus via the coronary sinus using distal and proximal anchors connected by a shaping ribbon. Designed for heart failure patients with functional mitral regurgitation (FMR) grades 2+ to 4+. CE Marked, MDR certified, and TGA approved; under U.S. EMPOWER pivotal trial for FDA approval.

Quantifiable outcome

  • 97% of patients maintained stable or improved MR grade across all time points through five years
  • +6 more outcomes

Companies that use Cardiac Dimensions

Customer profile

Named customers5 records

Segments3 records

Ideal customer profiles1 record

Cardiac Dimensions technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Cardiac Dimensions partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core.

  • Qtis.aicoreTechnology or Integration · 10 July 2026Qtis.ai launched its AI-native Clinical Trial Management System (CTMS) with Cardiac Dimensions as the first commercial customer. Cardiac Dimensions will use Qtis.ai's platform for clinical trial management including document management and integrated research operations.
  • Cleveland CliniccoreStrategic or Co-development Partner · 5 January 2023Leading center participating in the EMPOWER pivotal trial. Dr. Samir Kapadia serves as national principal investigator for the trial.
  • Columbia University Medical CentercoreStrategic or Co-development Partner · 5 January 2023Leading center participating in the EMPOWER pivotal trial for U.S. regulatory approval.
  • Ronald Reagan UCLA Medical CentercoreStrategic or Co-development Partner · 5 January 2023Leading center participating in the EMPOWER pivotal trial for U.S. regulatory approval.
  • European Society of CardiologycoreStrategic or Co-development Partner · 22 September 2021ESC Guidelines published recommendations supporting the Carillon Mitral Contour System for treatment of secondary mitral regurgitation. First non-TEER device included in heart failure guidelines.

Scale indicators10 records

Recent moves7 records

Expansion highlights6 records

Cardiac Dimensions competitors and assessment

Company assessment

Emerging players

  • Corvia Medical: Corvia Medical develops the Corvia Atrial Shunt (IASD) for heart failure with preserved ejection fraction (HFpEF). It targets an overlapping heart failure patient population through a different interventional mechanism, sharing potential referral channels and clinical thought leaders.
  • Ancora Heart: Ancora Heart is developing the AccuCinch ventricular restoration system for heart failure patients with functional mitral regurgitation. It is an emerging player addressing an overlapping patient population via a different mechanism (ventricular reshaping rather than annular).
  • Polares Medical: Polares Medical is developing a transcatheter mitral valve replacement (TMVR) technology targeting functional mitral regurgitation. It is an emerging structural heart company in the same clinical space with a complementary therapeutic approach.
  • NeoChord: NeoChord develops transcatheter chordal repair technology for degenerative mitral regurgitation using a transapical approach. It is an emerging player in the minimally invasive mitral valve repair space with a different but adjacent technology approach.
  • Valcare Medical: Valcare Medical is developing transcatheter mitral and tricuspid valve repair and replacement technologies. It is an emerging Israeli medical device company focused on structural heart interventions with overlapping therapeutic goals.
  • V-Wave Ltd. V-Wave is developing interatrial shunts for heart failure with preserved and reduced ejection fraction. While targeting a different mechanism, both companies address the same heart failure population and have overlapping clinical and commercial channels.

Broad incumbents

  • Medtronic: Medtronic is developing the Intrepid transcatheter mitral valve replacement (TMVR) system and has broader structural heart portfolio including the Intrepid, Evolut, and Harmony platforms. It is a broad incumbent in cardiovascular devices with overlapping mitral valve treatment ambitions.
  • Boston Scientific: Boston Scientific has a structural heart portfolio and has invested in transcatheter mitral and tricuspid valve technologies through acquisitions and partnerships. It competes in the broader cardiovascular space with relevant mitral valve repair and replacement programs.

Direct peers

  • Edwards Lifesciences: Edwards Lifesciences markets the PASCAL transcatheter valve repair system for mitral regurgitation, directly competing with both Carillon and MitraClip. The company is a major structural heart player with overlapping catheter-based mitral valve repair technology.
  • Abbott: Abbott markets the MitraClip, the leading transcatheter edge-to-edge repair (TEER) device for mitral regurgitation. It is the most commercially successful transcatheter mitral valve repair product and the primary direct competitor to Cardiac Dimensions' Carillon system for treating functional mitral regurgitation.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Cardiac Dimensions social profiles

Digital presence

Cardiac Dimensions compliance and trust

Trust signal

Compliance4 records

Cardiac Dimensions financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Cardiac Dimensions leadership team

Management profile

Number of profiles

Profiles9 records

Cardiac Dimensions subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Cardiac Dimensions funding detail

Funding detail

Funding overview

Funding rounds11 records

Investors24 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Cardiac Dimensions M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cardiac Dimensions

What does Cardiac Dimensions do?

Cardiac Dimensions develops and commercializes the Carillon Mitral Contour System, a catheter-based, minimally invasive device designed to treat functional mitral regurgitation (FMR) in heart failure patients. The device is delivered percutaneously via the coronary sinus and uses distal and proximal anchors connected by a shaping ribbon to reshape the mitral valve apparatus without damaging valve leaflets. It is sold directly to hospitals and cardiac catheterization labs in Europe and Australia, while U.S. use is limited to investigational settings via the EMPOWER pivotal trial.

Is Cardiac Dimensions a public or private company?

Cardiac Dimensions is a private company. It is classified as venture growth investor backed and is currently operating.

When was Cardiac Dimensions founded?

Cardiac Dimensions was founded in 2001. It employs 51 to 100 people.

Where is Cardiac Dimensions based?

Cardiac Dimensions is headquartered in Kirkland, United States, in the North America region.

How does Cardiac Dimensions make money?

One revenue line is on record: carillon Mitral Contour System Sales.

Who are Cardiac Dimensions's main competitors?

Emerging players on record are Corvia Medical, Ancora Heart, Polares Medical, NeoChord, Valcare Medical and V-Wave Ltd.. Broad incumbents are Medtronic and Boston Scientific. Direct peers are Edwards Lifesciences and Abbott.

Does Cardiac Dimensions have an API?

No public API is recorded for Cardiac Dimensions.

What industry is Cardiac Dimensions in?

Cardiac Dimensions's product category is Transcatheter Mitral Valve Repair Devices. Its primary akta.pro industry code is HLAHAFAL, Cardiac Assist & Heart Failure Therapies (Implantables, Neuromodulation), with a secondary code of HLAHAFAB, Structural Heart Valves (TAVR/SAVR) & Valve Repair. Its NAICS code is 334510 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business Wire BlogQtis.ai Launches AI-Native Clinical Research Division, Enters Fast-Growing $7.4 Billion CTMS MarketQtis.ai announced the launch of its Clinical Research Division and the commercial deployment of its AI-native Clinical Trial Management System, marking the company's entry into the healthcare software market. The first commercial customer is Cardiac Dimensions, a privately held medical device company developing catheter-based technologies for heart failure treatment. The global CTMS market is projected to grow from $2.4 billion in 2025 to $7.4 billion by 2033, and Qtis plans to expand its clinical research platform with additional enterprise solutions including electronic data capture and document management.FinancialContent Business PageQtis.ai Launches AI-Native Clinical Research Division, Enters Fast-Growing $7.4 Billion CTMS MarketQtis.ai announced the launch of its Clinical Research Division and the commercial deployment of its AI-native Clinical Trial Management System (CTMS), marking the company's entry into the global CTMS market. The company's first CTMS customer is Cardiac Dimensions, a privately held medical device company headquartered in Kirkland, Washington, that develops catheter-based technologies for heart failure treatment. Qtis plans to expand its clinical research platform with additional enterprise solutions including electronic data capture, document management, and integrated research operations platforms targeting sponsors, CROs, medical device companies, and research institutions.MassDeviceCardiac Dimensions data highlights durability, performance of mitral annuloplasty deviceCardiac Dimensions published three manuscripts providing clinical evidence supporting its Carillon mitral contour system for transcatheter indirect mitral annuloplasty. The five-year CINCH FMR registry data showed nearly half of 228 patients were free from heart failure hospitalizations, with 97% maintaining stable or improved mitral regurgitation grade and a 1.8% serious adverse event rate. The company is leveraging the data to advance U.S. regulatory approval through the EMPOWER Trial and expand commercial presence in Europe.Business Wire BlogCardiac Dimensions® Announces Three Major Publications Demonstrating Long-Term Durability, Real-World Performance, and Broad Patient Benefit of the Carillon Mitral Contour System®Cardiac Dimensions announced three major peer-reviewed publications providing clinical evidence for its Carillon Mitral Contour System, spanning a five-year multi-center registry of 228 patients, the largest single-center experience with 204 patients, and ten-year survival follow-up data. The studies demonstrated sustained reduction in mitral regurgitation severity, with over 97% of patients maintaining stable or improved MR grade through five years and a 66% ten-year cardiovascular survival rate in an advanced heart failure population. The company is using these results to support its ongoing U.S. pivotal EMPOWER Trial and FDA regulatory submission process, while continuing commercial expansion in Europe where the device holds CE Mark clearance.Towards HealthcareCardiovascular Devices Market Grows USD 156.33 Bn by 2034The global cardiovascular devices market is projected to grow from USD 78.13 billion in 2024 to USD 156.33 billion by 2034, representing a compound annual growth rate of 7.24%, driven by increasing cardiovascular disease prevalence and technological innovations including AI integration and minimally invasive procedures. North America held approximately 36% market share in 2024, while Asia Pacific is expected to be the fastest-growing region during the forecast period; interventional cardiology devices led by product type with 32% share, and hospitals remained the dominant end-user segment at 55%. Key recent developments include Abu Dhabi Investment Authority's $200 million investment in Meril, Cardiac Dimensions securing $53 million in Series E funding, and OMRON Healthcare partnering with Tricog Health for remote cardiac care platforms.Business Wire BlogWilliam T. Abraham, MD, Joins Cardiac Dimensions as Chief Medical OfficerCardiac Dimensions appointed William T. Abraham, MD, as Chief Medical Officer to lead clinical and regulatory strategies for its Carillon Mitral Contour System. Dr. Abraham will oversee the pivotal U.S. EMPOWER Trial aimed at securing FDA approval while supporting the device's existing commercial sales in Europe. This leadership addition leverages his extensive experience in heart failure therapies and large-scale clinical trials.MedicaldesignandoutsourcingHow Cardiac Dimensions made the Carillon Mitral Contour SystemCardiac Dimensions is developing the Carillon Mitral Contour System, a minimally invasive nitinol implant for treating mitral valve regurgitation, which currently has European approval and reimbursement. The company is manufacturing the implants in-house using specialized nitinol expertise while outsourcing catheter production, and is conducting the Empower pivotal trial to secure U.S. FDA approval. President Rick Wypych indicated that $53 million raised in March should be sufficient funding through the anticipated late 2027 submission for premarket approval.GeekWireCardiac Dimensions lands $53M to fund research and expansion of heart valve technologyCardiac Dimensions, a Kirkland, Washington-based medical device company, has raised $53 million in Series E funding to advance its Carillon Mitral Contour System for treating mitral valve regurgitation and support global commercial expansion. The round, bringing total funding to over $200 million, was led by Ally Bridge Group and included new investor Claret Capital Partners alongside existing investors Hostplus, M.H. Carnegie, Horizon 3 Healthcare, Lumira Ventures, and a confidential strategic investor. The company, which employs 65 people across offices in Kirkland, Sydney, and Frankfurt, is currently enrolling patients in a fifth clinical trial being conducted in the U.S. and other locations, while the device is commercially available in Europe and countries following European approvals.Ally Bridge GroupPrivate Equity Portfolio News: Cardiac Dimensions Raises $53 Million Series E FinancingCardiac Dimensions closed a $53 million Series E financing round led by Ally Bridge Group to fund the EMPOWER Trial U.S. pivotal study and commercialize its Carillon Mitral Contour System. The company plans to use the funds for global commercial expansion of the therapy.BioSpaceCardiac Dimensions Raises $53 Million Series E FinancingCardiac Dimensions closed a $53 million Series E financing round led by Ally Bridge Group to fund the EMPOWER Trial U.S. pivotal study and commercialize its Carillon Mitral Contour System. The company plans to use the funds for global commercial expansion of the therapy.